[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356860-105":59,"doc-detail-356860-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","high-risk-ebv-promotes-immune-evasion-in-nasopharyngeal-carcinoma-by-upregulating-hla-dp-via-the-encoded-balf2-hr-variant","High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant","","High-risk Epstein-Barr virus (EBV) reshapes immune recognition in nasopharyngeal carcinoma (NPC) by driving immune evasion pathways centered on HLA class II. The study identifies the EBV BALF2-HR variant as a key risk-associated change that upregulates HLA-DP, enabling interaction with LAG-3 on CD8+ T cells to suppress cytokine secretion and promote T-cell exhaustion. BALF2-HR enhances HLA-DP transcription through KPNA2-dependent facilitation of CIITA nuclear translocation, and combined anti-LAG-3 plus anti-PD-1 immunotherapy improves NPC treatment outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/high-risk-ebv-promotes-immune-evasion-in-nasopharyngeal-carcinoma-by-upregulating-hla-dp-via-the-encoded-balf2-hr-variant/356860/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/high-risk-ebv-promotes-immune-evasion-in-nasopharyngeal-carcinoma-by-upregulating-hla-dp-via-the-encoded-balf2-hr-variant/356860.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the role of BALF2-HR in NPC risk?","Question",{"text":113,"@type":114},"BALF2-HR is a high-risk EBV variant associated with increased NPC susceptibility. It alters immune recognition by upregulating HLA class II molecules, especially HLA-DP.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does increased HLA-DP contribute to immune evasion?",{"text":118,"@type":114},"HLA-DP engages LAG-3 on CD8+ T cells, inhibiting cytokine secretion and promoting T-cell exhaustion. These effects weaken anti-tumor immune responses.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is anti-LAG-3 combined with anti-PD-1 important?",{"text":122,"@type":114},"The document reports that conjunctive immunotherapy with anti-LAG-3 and anti-PD-1 antibodies significantly improves NPC treatment. This suggests LAG-3–mediated pathways contribute to resistance to anti-PD-1 alone.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356860,1790702600,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-70725-4](https://doi.org/10.1038/s41467-026-70725-4)  \nHigh-risk EBV promotes immune evasion innasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant  \nReceived: 7 January 2025  \n\n| Accepted: 4 March 2026 |\n| --- |\n| |\n| Check for updates |\n\nYi Meng1,2,7, Qian Wang1,2,7, Lei Shi3,7, Qijia Yan2,4, Qianqian He1,2,  \nPinglang Ruan1,2, Ziwei Chen1,2, Dan Wang2, Hongke Qu2, Pan Chen1,2, Zhaojian Gong 3, Fuyan Wang1,2, Bo Xiang 1,2,5, Ming Zhou1,2, Ming Tan 2,6, Guiyuan Li1,2, Can Guo 1,2,5, Zhaoyang Zeng 1,2 , Junshang Ge 1,2,5  & Wei Xiong 1,2,5   \nNasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia, with genetic factors playing a signiﬁcant role in its occurrence. The HLA gene region on chromosome 6 is linked to NPC susceptibility, but the mechanisms remain unclear. Epstein-Barr virus (EBV) infection is a well-established cause, with 95% of NPC patients being EBV-positive. Three key variations in the EBV genome (162215_C, 162476_C, 163364_T) in the BALF2 gene are strongly associated with NPC risk. This study ﬁnds that the high-risk BALF2 variant (BALF2-HR) upregulatesHLA class II molecules, such asHLA-DP, which interacts with LAG-3 on CD8⁺ T cells, inhibiting cytokine secretion and promoting T cell exhaustion, leading to immune evasion and reduced anti-PD-1 efﬁcacy. BALF2-HR also enhances HLA-DP transcription by binding to KPNA2 and facilitating CIITA nuclear translocation. Conjunctive immunotherapy with anti-LAG-3 and antiPD-1 antibodies signiﬁcantly improves NPC treatment. This work introduces anew therapeutic strategy for NPC and insights into infection-associated cancers.  \nEBV, the ﬁrst recognized human oncogenic virus1, infects over 90% of the world’s adult population. However, most infected individuals remain asymptomatic, with only a small fraction developing malignancies. The EBV infects human cells and expresses viral proteins and non-coding RNAs that promote cell proliferation, inhibit cell death, and enable immune evasion. Over time, these changes drive the malignant transformation of infected cells, ultimately leading to the formation of tumors2. EBV has been linked to various lymphomas, including Burkitt lymphoma3, Hodgkin lymphoma4, and NK/T-cell  \nlymphoma5, as well as epithelial malignancies such as NPC, where over 95% of cases are EBV-positive and EBV-associated gastric carcinoma (EBVaGC), which constitutes 10% of gastric cancers6, contributing to over 200,000 cases annually and 1.8% of cancer-related deaths worldwide. Among these EBV-associated cancers, only NPC displays asigniﬁcant geographic concentration7,8. NPC is most prevalent in North Africa, Southeast Asia, and southern China, accounting for approximately 50% of global NPC cases6,9,10. The etiology of NPC involves a combination of genetic predisposition, environmental and dietary  \n1NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Afﬁliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. 2Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medical Sciences, Central South University, Changsha, Hunan, China. 3Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 4Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 5Furong Laboratory, Changsha, Hunan, China. 6Institute of Biochemistry & Molecular Biology, and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan. 7These authors contributed equally: Yi Meng, Qian Wang, Lei Shi.  \ne-mail: [zengzhaoyang@csu.edu.cn](zengzhaoyang@csu.edu.cn); [gejunshang@csu.edu.cn](gejunshang@csu.edu.cn); [xiongwei@csu.edu.cn](xiongwei@csu.edu.cn)  \ncarcinogens2,6,11, which also suggests the presence of speciﬁc high-risk EBV subty","cbCaiomHays6Ib39","https://ap.wps.com/l/cbCaiomHays6Ib39","pdf",9845639,"English","# Introduction\n# EBV variants and NPC risk\n# Immune evasion and checkpoint resistance\n# Mechanistic findings and therapeutic implications","[{\"question\":\"What is the role of BALF2-HR in NPC risk?\",\"answer\":\"BALF2-HR is a high-risk EBV variant associated with increased NPC susceptibility. It alters immune recognition by upregulating HLA class II molecules, especially HLA-DP.\"},{\"question\":\"How does increased HLA-DP contribute to immune evasion?\",\"answer\":\"HLA-DP engages LAG-3 on CD8+ T cells, inhibiting cytokine secretion and promoting T-cell exhaustion. These effects weaken anti-tumor immune responses.\"},{\"question\":\"Why is anti-LAG-3 combined with anti-PD-1 important?\",\"answer\":\"The document reports that conjunctive immunotherapy with anti-LAG-3 and anti-PD-1 antibodies significantly improves NPC treatment. This suggests LAG-3–mediated pathways contribute to resistance to anti-PD-1 alone.\"}]","High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant | PDF",1790127758,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a1fc73f3c6b3f6f2ba83313163c38ff.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac8125198a0747ab5e0f6c43fb956fc9.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6aab255768ec387821028813cd987ca.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca0fd6713ce1deaffd07d845eee6aed6.webp",980,1301]